Gladius Capital Management’s Biogen BIIB Stock Holding History

Gladius Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-600	Closed	-$161K	–	360
2022 Q3	$161K	Buy	+600	New	+$127K	0.01%	156

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gladius Capital Management's BIIB Position: Q1 2024 in Review

Gladius Capital Management sold out of Biogen (BIIB) in Q1 2024, closing a stake of 141 shares — an estimated $36.5K sold.

Gladius Capital Management first reported a position in BIIB in Q4 2018 and held it in 6 quarters. The position peaked at $993K in Q1 2019. 954 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Gladius Capital Management reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Gladius Capital Management sold 141 Biogen shares in Q1 2024, an estimated $36.5K.
Gladius Capital Management first reported a position in Biogen in Q4 2018 and held it in 6 quarters.
Gladius Capital Management's Biogen position peaked at $993K in Q1 2019.
954 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Gladius Capital Management's 13F filing for Q1 2024, filed 14 May 2024.